Abstract
Systemic anticancer therapies may produce several toxicities including eye adverse events. In fact, contrary to general belief, the eye is a really sensitive organ. These adverse events may vary between a simple lacrimation to a marked irreversible visual loss even at therapeutic doses. A review of the literature was conducted showing that ocular toxicity is not as uncommon as previously thought and unfortunately in most cases, the mechanism underlying this continue to be poorly understood. Dealing with this toxicity is relevant and a close collaboration between oncologists, ophthalmologists and pharmacists would be advisable to reduce the incidence of serious toxicities.
Keywords: Ocular toxicity, chemotherapy toxicity, epiphora, excessive lacrimation.
Current Cancer Therapy Reviews
Title:Ocular Toxicities in Cancer Therapy: Still Overlooked
Volume: 10 Issue: 1
Author(s): Esther Una Cidon and Pilar Alonso
Affiliation:
Keywords: Ocular toxicity, chemotherapy toxicity, epiphora, excessive lacrimation.
Abstract: Systemic anticancer therapies may produce several toxicities including eye adverse events. In fact, contrary to general belief, the eye is a really sensitive organ. These adverse events may vary between a simple lacrimation to a marked irreversible visual loss even at therapeutic doses. A review of the literature was conducted showing that ocular toxicity is not as uncommon as previously thought and unfortunately in most cases, the mechanism underlying this continue to be poorly understood. Dealing with this toxicity is relevant and a close collaboration between oncologists, ophthalmologists and pharmacists would be advisable to reduce the incidence of serious toxicities.
Export Options
About this article
Cite this article as:
Cidon Una Esther and Alonso Pilar, Ocular Toxicities in Cancer Therapy: Still Overlooked, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152249
DOI https://dx.doi.org/10.2174/157339471001140815152249 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Comparison of Large Proteomic Datasets
Current Proteomics Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets A Closer Look at α-Secretase
Current Alzheimer Research Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Molecular Insight and Binding Pattern Analysis of Shikonin as a Potential VEGFR-2 Inhibitor
Current Enzyme Inhibition Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Potentials of Polymeric Nanoparticle as Drug Carrier for Cancer Therapy: With a Special Reference to Pharmacokinetic Parameters
Current Drug Metabolism Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Cancer Estimates in Brazil Reveal Progress for the Most Lethal Malignancies
Current Topics in Medicinal Chemistry Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Towards Understanding the Roles of Prohibitins, Multi-Functional Regulator Proteins
Current Chemical Biology Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments
Current Medicinal Chemistry Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Drug Analogs of COX-2 Selective Inhibitors Lumiracoxib and Valdecoxib Derived from in silico Search and Optimization
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry